Skip to content
HowShorted

Medifast, Inc. short interest in 2023

In 2023, Medifast, Inc.'s disclosed short interest ran from 5.39% of shares outstanding on 13 Jan 2023 to 15.89% on 29 Dec 2023, a change of +10.50 percentage points. The year's high was 16.75% on 30 Nov 2023 and its low 5.39% on 13 Jan 2023, averaging 14.11% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.15 days on 30 Nov 2023. Full history: Medifast, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Medifast, Inc. in 2023

2023 in figures

Start of year
5.39% (13 Jan 2023)
End of year
15.89% (29 Dec 2023)
Change
+10.50 pp
High
16.75% (30 Nov 2023)
Low
5.39% (13 Jan 2023)
Average
14.11%
Highest days to cover
13.15 (30 Nov 2023)
SEC filings marked
8

Every report in 2023

Medifast, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20235.39%5.47
31 Jan 20237.81%5.05
15 Feb 202310.91%5.98
28 Feb 202314.28%4.5510-K filed, results (8-K)
15 Mar 202314.06%7.62
31 Mar 202314.17%7.70
14 Apr 202314.55%8.75
28 Apr 202315.85%8.48
15 May 202314.97%4.9010-Q filed, results (8-K)
31 May 202314.22%8.52
15 Jun 202314.56%9.47
30 Jun 202314.49%5.19
14 Jul 202313.35%8.19
31 Jul 202313.40%9.04
15 Aug 202313.80%7.6310-Q filed, results (8-K)
31 Aug 202314.94%10.95
15 Sep 202315.26%9.94
29 Sep 202316.13%10.66
13 Oct 202315.98%9.58
31 Oct 202315.89%12.85
15 Nov 202315.42%6.8810-Q filed, results (8-K)
30 Nov 202316.75%13.15
15 Dec 202316.53%5.23
29 Dec 202315.89%10.98

See also: Medifast, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.